We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.50 | 61.00 | 62.00 | 62.00 | 61.50 | 61.50 | 4,192 | 08:00:13 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
From Apr 2019 to Apr 2024
TIDMTRX
RNS Number : 2885Q
Tissue Regenix Group PLC
18 February 2019
Tissue Regenix Group plc
Change of Adviser
Leeds, 18 February 2019 - Tissue Regenix Group (AIM: TRX) ("Tissue Regenix" or the "Company") the regenerative medical devices company, today announces the appointment of Stifel Nicolaus Europe Limited as Nominated Adviser and Broker to the Company, with immediate effect.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 / Caitlin Pearson, Head of Communications 07920 272441 --------------------------------------------- ------------------------- Stifel Nicolaus Europe Limited (Nominated Tel: +44 (0)20 7710 7600 Adviser and Broker) Jonathan Senior / Alex Price / Ben Maddison --------------------------------------------- ------------------------- FTI Consulting Tel: +44 (0)203 727 1000 Brett Pollard / Victoria Foster Mitchell / Mary Whittow ============================================= =========================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
APPMMGMZMNDGLZZ
(END) Dow Jones Newswires
February 18, 2019 02:01 ET (07:01 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
